A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia.
Ventura A SimonovichLeandro D Burgos PratxPaula ScibonaMaría V BerutoMarcelo G ValloneCarolina VázquezNadia SavoyDiego Hernán GiuntaLucía G PérezMarisa Del L SánchezAndrea Vanesa GamarnikDiego S OjedaDiego M SantoroPablo J CaminoSebastian AnteloKarina RaineroGabriela P VidiellaErica A MiyazakiWanda CornisteinOmar A TrabadeloFernando M RossMariano SpottiGabriel FuntowiczWalter E ScordoMarcelo H LossoInés FerniotPablo E PardoEulalia RodriguezPablo RucciJulieta PasqualiNora A FuentesMariano EsperattiGerardo A SperoniEsteban C NanniniAlejandra MatteaccioHernán G MichelangeloDean FollmannH Clifford LaneWaldo H Bellosonull nullPublished in: The New England journal of medicine (2020)
No significant differences were observed in clinical status or overall mortality between patients treated with convalescent plasma and those who received placebo. (PlasmAr ClinicalTrials.gov number, NCT04383535.).